VIVES is a multi-sector fund that invests in projects with a positive societal impact
ViroVet is a pioneering company developing innovative technologies to combat viral diseases in livestock. They focus on antiviral drugs for complex respiratory illnesses and novel vaccines to protect...
Axinesis is a spin-off of the Université Catholique de Louvain (BE), which has a clear mission: to improve the functional recovery of patients through innovative and accessible technologies dedicated...
Novadip was founded in 2013 as spin-off comany from Université Catholique de Louvain and St. Luc University Hospital, based on the scientific discoveries of professor and founder Dr. Denis Dufrane...
Chris Buyse, co-founder and Managing Partner of Fund+:
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Willem de Vos, Prof. at University of Wageningen; Patrice Cani, Prof. at UCLouvain; Jean-Christophe Malrieu, CEO A-Mansia:
"As founders and CEO of A-mansia BioTech we experienced essential support...
Philippe Mengal, past CEO Greenwatt:
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to